CoChat

Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Polycystic ovary syndrome is a complex and heterogenous disorder involving multiple organ systems and different molecular pathways. It is tightly associated with obesity and especially abdominal obesity. As body weight reduction is the main modifiable risk factor for polycystic ovary syndrome, therapeutic approaches in overweight or obese women with polycystic ovary syndrome have been developed. Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus. The majority of current clinical studies have demonstrated that liraglutide therapy achieved significant reductions in body weight, body mass index, and abdominal circumference in overweight and obese women with polycystic ovary syndrome. Liraglutide therapy promoted significant improvements in free testosterone and sex hormone-binding globulin levels in some studies. Important metabolic and hormonal improvements were also reported after the combination of liraglutide with metformin. Increased menstrual frequency, as well as potential positive effects in reproduction, were described. However, the small number of participants, short duration, and low daily liraglutide dose are some of the main limitations of these studies. Larger and longer, multi-centred, double-blind, placebo-controlled trials of liraglutide monotherapy or combination therapy, with prolonged post-interventional monitoring, are crucially anticipated. Metabolic, hormonal, and reproductive primary outcomes should be uniformly addressed, to tailor future targeted treatment approaches, according to the patient phenotype and needs. This will improve long-term therapeutic outcomes in this population.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40261-020-00942-2

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 119 · Cited by 25

Research works printed but not linked: 1

  1. Gao LH, Zhang CL, Liu XY, Liu J, Zhong CF. Pilot clinical study of the efficacy of liraglutide in treating polycystic ovary syndrome patients with type 2 diabetes mellitus. Clin Focus. 2016;31:539–42.

Metadata

Authors
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S.
Affiliations
  • Paphos General Hospital (CY)
  • CDA College (CY)
Corresponding author
Papaetis, Georgios S.
Venue
Clinical Drug Investigation
Published
2020-06-24
Volume
40
Issue
8
Pages
695-713
ISSN
  • 0114-2402 (ISSN-L)
  • 1173-2563
  • 1179-1918
OpenAlex
W3037161063
Cited by
25
References
119
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 5 · 2022: 6 · 2021: 6
FWCI
0.63
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Clinical Drug Investigation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
liraglutide, polycystic ovary syndrome, obesity, abdominal obesity, weight loss, GLP-1 receptor agonists, metformin combination therapy, free testosterone, sex hormone-binding globulin, menstrual frequency, reproductive outcomes, body mass index
MeSH terms
Liraglutide, Adult, Body Weight, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Metformin, Middle Aged, Obesity, Polycystic Ovary Syndrome, Weight Loss, Body Mass Index, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. https://app.cochat.ai/papers/10.1007/s40261-020-00942-2
The paper
Papaetis, G. S., Filippou, P. K., Constantinidou, K. G., & Stylianou, C. S. (2020). Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. Clinical Drug Investigation. https://doi.org/10.1007/s40261-020-00942-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.